跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 36,171 条关于
“FGFR1-3”
全部
36,171
临床试验
17,873
药物
4,686
机构
1,356
资讯
12,256
去年
Rogaratinib Plus Atezolizumab Shows Promise in Cisplatin-Ineligible Urothelial Cancer
去年
JNJ-2113 Shows Promise for Psoriasis, Infigratinib for Achondroplasia, and Gildeuretinol Gains FDA Support for Stargardt Disease
去年
BridgeBio's Attruby Sees Strong Early Demand; Phase 3 Trials Fully Enrolled
去年
Infigratinib Shows Promise in Phase 2 Trial for Children with Achondroplasia
去年
Rogaratinib Plus Atezolizumab Shows Promise in FGFR mRNA-Overexpressing Urothelial Cancer
去年
Oral Infigratinib Shows Promise for Children with Achondroplasia
去年
BridgeBio Reports Positive Pipeline Progress and Q3 2024 Financial Results
去年
Targeted Therapies Transform Biliary Tract Cancer Treatment Landscape with FGFR2 Inhibitors Leading Clinical Advances
前天
HLB's Elevar Submits EMA Marketing Application for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma
去年
Eisai Seeks Japanese Approval for Novel FGFR Inhibitor Tasurgratinib in Biliary Tract Cancer
第 1 页,共 1226 页
上一页
下一页